High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2

Leukemia Research

Volumn 35, Issue 6, 2011, Pages 741-749

  Chamuleau, M E D ^a   Ossenkoppele, G J ^a   van Rhenen, A ^a   van Dreunen, L ^a   Jirka, S M G ^a   Zevenbergen, A ^a   Schuurhuis, G J ^a   van de Loosdrecht, A A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Apoptosis; Human monoclonal antibodies; Immunotherapy; TRAIL

Indexed keywords

DEATH RECEPTOR 5; LEXATUMUMAB; MAPATUMUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; APOPTOSIS; BONE MARROW CELLS; CELL LINE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GPI-LINKED PROTEINS; HL-60 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PROGNOSIS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR DECOY RECEPTORS; U937 CELLS; YOUNG ADULT;

EID: 79955620753     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.12.032     Document Type: Article

References (42)

1. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999, 189(May):1451-1460.
2. Smyth M.J., Cretney E., Takeda K., Wiltrout R.H., Sedger L.M., Kayagaki N., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001 Mar 19, 193:661-670.
3. Fanger N.A., Maliszewski C.R., Schooley K., Griffith T.S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 1999, 190(October):1155-1164.
4. Griffith T.S., Wiley S.R., Kubin M.Z., Sedger L.M., Maliszewski C.R., Fanger N.A. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999, 189:1343-1354.
5. Bodmer J.L., Holler N., Reynard S., Vinciguerra P., Schneider P., Juo P., et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000, 2:241-243.
6. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000, 12:611-620.
7. Younes A., Kadin M.E. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003, 21(September):3526-3534.
8. Degli-Esposti M.A., Smolak P.J., Walczak H., Waugh J., Huang C.P., DuBose R.F., et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997, 186(October):1165-1170.
9. Merino D., Lalaoui N., Morizot A., Schneider P., Solary E., Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006, 26:7046-7055.
10. Strater J., Moller P. TRAIL and viral infection. Vitam Horm 2004, 67:257-274.
11. Secchiero P., Melloni E., Heikinheimo M., Mannisto S., Di P.R., Iacone A., et al. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 2004, 103(January):517-522.
12. Secchiero P., Gonelli A., Mirandola P., Melloni E., Zamai L., Celeghini C., et al. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 2002, 100(October):2421-2429.
13. Choi J.W. Relationships between tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and hematopoietic activity in healthy adults. Ann Hematol 2005, 84:728-733.
14. Zamai L., Secchiero P., Pierpaoli S., Bassini A., Papa S., Alnemri E.S., et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000, 95(June):3716-3724.
15. Lum J.J., Bren G., McClure R., Badley A.D. Elimination of senescent neutrophils by TNF-related apoptosis-inducing ligand. J Immunol 2005, 175(July):1232-1238.
16. Cretney E., Takeda K., Yagita H., Glaccum M., Peschon J.J., Smyth M.J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002, 168(February):1356-1361.
17. Takeda K., Smyth M.J., Cretney E., Hayakawa Y., Kayagaki N., Yagita H., et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002, 195(January):161-169.
18. Ashkenazi A., Holland P., Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008, 26:3621-3630.
19. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002, 2:420-430.
20. Min Y.J., Lee J.H., Choi S.J., Chi H.S., Lee J.S., Kim W.K., et al. Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia. Leuk Res 2004, 28:359-365.
21. Snell V., Clodi K., Zhao S., Goodwin R., Thomas E.K., Morris S.W., et al. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 1997, 99:618-624.
22. Cappellini A., Mantovani I., Tazzari P.L., Grafone T., Martinelli G., Cocco L., et al. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts. Int J Mol Med 2005, 16:1041-1048.
23. Riccioni R., Pasquini L., Mariani G., Saulle E., Rossini A., Diverio D., et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 2005, 90:612-624.
24. Carter B.Z., Mak D.H., Schober W.D., Dietrich M.F., Pinilla C., Vassilev L.T., et al. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 2008, 111(April):3742-3750.
25. Rosato R.R., Almenara J.A., Coe S., Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 2007, 67(October):9490-9500.
26. Secchiero P., Zerbinati C., di Iasio M.G., Melloni E., Tiribelli M., Grill V., et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 2007, 8:395-403.
27. Wuchter C., Krappmann D., Cai Z., Ruppert V., Scheidereit C., Dorken B., et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia 2001, 15:921-928.
28. Jones D.T., Ganeshaguru K., Mitchell W.A., Foroni L., Baker R.J., Prentice H.G., et al. Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand. Br J Haematol 2003, 121:713-720.
29. Georgakis G.V., Li Y., Humphreys R., Andreeff M., O'Brien S., Younes M., et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005, 130:501-510.
30. Takeda K., Yamaguchi N., Akiba H., Kojima Y., Hayakawa Y., Tanner J.E., et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004, 199(February):437-448.
31. Pukac L., Kanakaraj P., Humphreys R., Alderson R., Bloom M., Sung C., et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005, 92(April):1430-1441.
32. Humphreys R.C., Halpern W. Trail receptors: targets for cancer therapy. Adv Exp Med Biol 2008, 615:127-158.
33. Ashkenazi A., Herbst R.S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008, 118:1979-1990.
34. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:620-625.
35. Ziegler-Heitbrock H.W., Thiel E., Futterer A., Herzog V., Wirtz A., Riethmuller G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer 1988, 41(March):456-461.
36. van Rhenen A., Feller N., Kelder A., Westra A.H., Rombouts E., Zweegman S., et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005, 11(September):6520-6527.
37. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277(August):818-821.
38. Shiiki K., Yoshikawa H., Kinoshita H., Takeda M., Ueno A., Nakajima Y., et al. Potential mechanisms of resistance to TRAIL/Apo2L-induced apoptosis in human promyelocytic leukemia HL-60 cells during granulocytic differentiation. Cell Death Differ 2000, 7:939-946.
39. Chan F.K. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 2007, 37:101-107.
40. Mizutani Y., Nakanishi H., Yoshida O., Fukushima M., Bonavida B., Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 2002, 38:167-176.
41. Wu X.X., Kakehi Y., Mizutani Y., Nishiyama H., Kamoto T., Megumi Y., et al. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer 2003 Apr 20, 104:409-417.
42. Wu X.X., Kakehi Y., Mizutani Y., Kamoto T., Kinoshita H., Isogawa Y., et al. Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int J Oncol 2002, 20:949-954.